Business
CLBIO: Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth
CLBIO: Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth
About this update from Corline Biomedical Ab
Q3 2025 marked a breakthrough with FDA approval for a partner's product using CHSTM, a 10-year supply deal, and a 23 MSEK capital raise. Despite lower sales and continued losses, the company expects improved financials from new agreements and US expansion.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
View stock analysis, news, and events for Corline Biomedical Ab